Physician profile
Supria Batra
NPI 1861830671
$2,986.18
in general payments reported to CMS, 2019-2025
18 companies · $1,057 in 2025
The $1,057 reported for 2025 was less than what a typical Advanced Heart Failure and Transplant Cardiology provider received nationally (typical 2025 total: $1,046).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $146 · 2020: $202 · 2021: $189 · 2022: $161 · 2023: $1,139 · 2024: $92.42 · 2025: $1,057.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,288.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,288.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,297.63 | 2020-2025 | Thoratec Heartmate 3 Lvas Implant Kit |
| Abiomed | $376.79 | 2021-2024 | Impella |
| Medtronic, INC. | $320.14 | 2023-2025 | Aurora Ev-Icd Mri Surescan, Cobalt Dr Mri Surescan, Micra |
| Bridgebio Pharma, INC. | $187.16 | 2025 | Attruby |
| Pfizer INC. | $122.83 | 2025 | |
| Novo Nordisk INC | $119.70 | 2025 | Ozempic |
| E.R. Squibb & Sons, L.L.C. | $112.18 | 2025 | Camzyos, Eliquis |
| Amgen INC. | $86.62 | 2019-2025 | Repatha |
| Alnylam Pharmaceuticals INC. | $82.13 | 2025 | Amvuttra |
| Novartis Pharmaceuticals Corporation | $65.60 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $49.94 | 2025 | Verquvo, Capvaxive |
| Portola Pharmaceuticals, LLC | $28.03 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $26.68 | 2025 | Farxiga |
| Angiodynamics, INC. | $24.10 | 2024 | Alphavac |
| Daiichi Sankyo INC. | $23.74 | 2024 | Injectafer |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.32 | 2020 | |
| Lilly USA, LLC | $21.49 | 2025 | Zepbound |
| Chiesi USA, INC. | $18.10 | 2025 | Juxtapid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Supria Batra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.